Eli Lilly and Company

Eli Lilly and Company
Eli Lilly and Company, converted to PNG by Huwmanbeing · Public domain · source
Name	Eli Lilly and Company
Type	Public
Traded as	NYSE: LLY
Industry	Pharmaceutical industry
Founded	1876
Founder	Eli Lilly
Headquarters	Indianapolis, Indiana, United States
Key people	David A. Ricks, Josh Smiley
Products	Pharmaceuticals
Revenue	$22.87 billion USD (2020)
Operating income	$4.33 billion USD (2020)
Net income	$3.24 billion USD (2020)
Total assets	$43.64 billion USD (2020)
Total equity	$14.54 billion USD (2020)
Num employees	33,815 (2020)
Subsidiaries	ImClone Systems, Avid Radiopharmaceuticals

Eli Lilly and Company is a renowned pharmaceutical company founded by Eli Lilly in 1876, with its headquarters located in Indianapolis, Indiana, United States. The company has a rich history of developing innovative medicines and has been a major player in the pharmaceutical industry for over a century, with notable collaborations with Pfizer, Merck & Co., and AstraZeneca. Eli Lilly and Company has been listed on the New York Stock Exchange (NYSE) under the ticker symbol LLY since 1952, and has been a constituent of the S&P 500 index since 1957, alongside other major pharmaceutical companies such as Johnson & Johnson and GlaxoSmithKline. The company's commitment to research and development has led to the development of numerous groundbreaking treatments, including insulin and prozac, in partnership with University of Toronto and National Institutes of Health.

● History

The company's history dates back to 1876 when Eli Lilly founded the business with a investment of $1,400, and it quickly gained recognition for its high-quality medicines, including morphine and codeine, which were developed in collaboration with Bayer and Merck KGaA. In the early 20th century, Eli Lilly and Company introduced insulin to the market, which revolutionized the treatment of diabetes mellitus, and was developed in partnership with University of Toronto and Harvard University. The company continued to expand its product portfolio throughout the 20th century, with notable introductions including prozac and gemzar, which were developed in collaboration with National Institutes of Health and Food and Drug Administration. Today, Eli Lilly and Company is one of the largest pharmaceutical companies in the world, with operations in over 125 countries, including United States, Canada, United Kingdom, Germany, and Australia, and partnerships with major healthcare organizations such as World Health Organization and American Medical Association.

● Products

Eli Lilly and Company has a diverse portfolio of pharmaceutical products, including humulin, cymbalta, and alitea, which are used to treat a range of conditions, including diabetes mellitus, depression, and cancer, and have been developed in collaboration with University of California, San Francisco and Duke University. The company's products are marketed under various brand names, including Lilly, ImClone Systems, and Avid Radiopharmaceuticals, and are distributed through a network of pharmacies and hospitals worldwide, including CVS Health and Walgreens Boots Alliance. Eli Lilly and Company has also developed a range of biotechnology products, including erbitux and cyramza, which are used to treat cancer and other serious diseases, and have been developed in partnership with Bristol-Myers Squibb and Roche Holding.

● Research and Development

Eli Lilly and Company has a strong commitment to research and development, with a focus on developing innovative treatments for serious diseases, including cancer, diabetes mellitus, and neurodegenerative disorders, in collaboration with National Cancer Institute and American Cancer Society. The company has a network of research centers and laboratories around the world, including facilities in Indianapolis, San Diego, and New York City, and partnerships with major research institutions such as Harvard University and Stanford University. Eli Lilly and Company has also established partnerships with other pharmaceutical companies, including Pfizer and Merck & Co., to develop new treatments and technologies, such as immunotherapy and gene therapy, in collaboration with University of Pennsylvania and Columbia University.

● Controversies

Eli Lilly and Company has been involved in several controversies over the years, including lawsuits related to the marketing of prozac and zyprexa, which were developed in collaboration with Food and Drug Administration and European Medicines Agency. The company has also faced criticism for its pricing practices, particularly with regards to insulin and other diabetes treatments, which have been developed in partnership with American Diabetes Association and Juvenile Diabetes Research Foundation. In addition, Eli Lilly and Company has been the subject of several product liability lawsuits, including cases related to thimerosal and vaccine safety, which have been investigated by Centers for Disease Control and Prevention and World Health Organization.

● Corporate Affairs

Eli Lilly and Company is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol LLY, and is a constituent of the S&P 500 index, alongside other major pharmaceutical companies such as Johnson & Johnson and Pfizer. The company's board of directors includes notable individuals such as David A. Ricks and Josh Smiley, who have previously held leadership positions at Merck & Co. and AstraZeneca. Eli Lilly and Company has also established partnerships with other healthcare organizations, including American Medical Association and World Health Organization, to promote public health and improve access to medicines worldwide, particularly in developing countries such as India and China. The company's commitment to corporate social responsibility has led to the development of several philanthropic programs, including the Lilly Foundation, which supports healthcare initiatives and education programs in United States and around the world, in partnership with Bill and Melinda Gates Foundation and World Bank.

Category:Pharmaceutical companies of the United States